These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31776206)

  • 21. (3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells.
    Wu P; Wang X; Ma Y; Xu X; Liu W; Sheng Z; Chen M; Zhou R; Zhang K; Goodin S; Zheng X; Li D
    Bioorg Chem; 2020 Aug; 101():104022. PubMed ID: 32599367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice.
    Selvanesan BC; Meena K; Beck A; Meheus L; Lara O; Rooman I; Gravekamp C
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33154149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
    Le HK; Graham L; Cha E; Morales JK; Manjili MH; Bear HD
    Int Immunopharmacol; 2009 Jul; 9(7-8):900-9. PubMed ID: 19336265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine treatment enhanced the anti-tumor effect of cytokine induced killer cells by depletion of CD4
    Zhao P; Zhu D; Zhang Z; Han B; Gao D; Wei X; Xie X; Li C; Sun W; Wang Q; Guo Q
    Immunol Lett; 2017 Jan; 181():36-44. PubMed ID: 27867030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
    Vincent J; Mignot G; Chalmin F; Ladoire S; Bruchard M; Chevriaux A; Martin F; Apetoh L; Rébé C; Ghiringhelli F
    Cancer Res; 2010 Apr; 70(8):3052-61. PubMed ID: 20388795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.
    Tongu M; Harashima N; Tamada K; Chen L; Harada M
    Cancer Sci; 2015 Jan; 106(1):9-17. PubMed ID: 25363339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications.
    Khan MA; Srivastava SK; Bhardwaj A; Singh S; Arora S; Zubair H; Carter JE; Singh AP
    Oncotarget; 2015 Nov; 6(36):39140-50. PubMed ID: 25970774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.
    Ding ZC; Lu X; Yu M; Lemos H; Huang L; Chandler P; Liu K; Walters M; Krasinski A; Mack M; Blazar BR; Mellor AL; Munn DH; Zhou G
    Cancer Res; 2014 Jul; 74(13):3441-53. PubMed ID: 24780756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
    Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
    J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury.
    Zhang C; Wang S; Li J; Zhang W; Zheng L; Yang C; Zhu T; Rong R
    Cell Death Dis; 2017 Mar; 8(3):e2695. PubMed ID: 28333137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
    Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
    Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.
    Ghansah T; Vohra N; Kinney K; Weber A; Kodumudi K; Springett G; Sarnaik AA; Pilon-Thomas S
    Cancer Immunol Immunother; 2013 Jun; 62(6):1083-91. PubMed ID: 23604104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
    Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
    Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
    BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
    J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Tumor Control of HER2 DNA Vaccines Is Achieved by an Alteration of Tumor Cells and Tumor Microenvironment by Gemcitabine and Anti-Gr-1 Ab Treatment in a HER2-Expressing Tumor Model.
    Danishmalik SN; Sin JI
    DNA Cell Biol; 2017 Sep; 36(9):801-811. PubMed ID: 28777668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
    Dolcetti L; Peranzoni E; Ugel S; Marigo I; Fernandez Gomez A; Mesa C; Geilich M; Winkels G; Traggiai E; Casati A; Grassi F; Bronte V
    Eur J Immunol; 2010 Jan; 40(1):22-35. PubMed ID: 19941314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modified method for differentiation of myeloid-derived suppressor cells
    Zhou H; Xie Z; Morikawa N; Sakurai F; Mizuguchi H; Okuzaki D; Okada N; Tachibana M
    Biochem Biophys Rep; 2023 Mar; 33():101416. PubMed ID: 36605123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.
    Porembka MR; Mitchem JB; Belt BA; Hsieh CS; Lee HM; Herndon J; Gillanders WE; Linehan DC; Goedegebuure P
    Cancer Immunol Immunother; 2012 Sep; 61(9):1373-85. PubMed ID: 22215137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.